Efficacy of allergen-specific immunotherapy in children with atopic dermatitis sensitized to house dust mites
Keywords:sublingual immunotherapy, atopic dermatitis, house dust mite, children
Background. Allergen-specific immunotherapy is the mainstay of treatment for inducing long-term immune and clinical tolerability of allergens in patients with IgE-mediated allergic diseases. The aim of this study was to investigate the role of sublingual immunotherapy (SLIT) as an adjunct treatment in children with atopic dermatitis sensitized to dust mites by conducting a randomized 18-month clinical trial with house dust mite extract or placebo. Materials and methods. The study included 26 children with atopic dermatitis who were sensitized to house dust mites. 12 patients received SLIT, and 14 controls received only symptomatic treatment. The activity of atopic dermatitis was assessed using the dynamics of SCORAD indicators and the СDLQI questionnaire. Results. After 18 months of treatment, the reduction in baseline SCORAD was 43.4 % in the SLIT group and 10.3 % in the placebo group (W = 104.0, p = 0.003). СDLQI also showed improvement in the SLIT treatment group (40.7 % in the SLIT group, no improvement was found in the control group, W = 106.5, p = 0.004). There were no significant differences in serum Der.p.-specific sIgE levels between the main and control groups 18 months after the start of treatment (p > 0.05). Conclusions. SLIT with dust mite extract can provide significant clinical efficacy among children with atopic dermatitis, as evidenced by a significant overall reduction in SCORAD scores and СDLQI questionnaire scores.
Volosovets ОP, Beketova GV, Berezenko VS, Mityuryaeva IA, Volosovets TN, Pochinok TV. Dynamics of Morbidity and Prevalence of Atopic Dermatitis in Children of Ukraine over the past 20 years: medical and environmental aspects. Paediatrics Eastern Europe. 2021;(2):206-216. (in Russian).
Matveeva SJu, Umanets TR. Effectiveness of sublingual allergen-specific immunotherapy in children with spring polynosis and pollen-food syndrome. World Science. 2019;2(3):34-41. doi:10.31435/rsglobal_ws/31032019/6409. (in Ukrainian).
Incorvaia C, Al-Ahmad M, Ansotegui IJ, et al. Personalized medicine for allergy treatment: Allergen immunotherapy still a unique and unmatched model. Allergy. 2021 Apr;76(4):1041-1052. doi:10.1111/all.14575.
Novak N, Bieber T, Hoffmann M, et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol. 2012 Oct;130(4):925-31.e4. doi:10.1016/j.jaci.2012.08.004.
Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol. 2013 Jul;132(1):110-117. doi:10.1016/j.jaci.2013.02.044.
Nahm DH, Kim ME, Kwon B, Cho SM, Ahn A. Clinical Efficacy of Subcutaneous Allergen Immunotherapy in Patients with Atopic Dermatitis. Yonsei Med J. 2016 Nov;57(6):1420-1426. doi:10.3349/ymj.2016.57.6.1420.
Zhou J, Chen S, Song Z. Analysis of the long-term efficacy and safety of subcutaneous immunotherapy for atopic dermatitis. Allergy Asthma Proc. 2021 Mar 1;42(2):e47-e54. doi:10.2500/aap.2021.42.200126.
Werfel T, Breuer K, Ruéff F, et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy. 2006 Feb;61(2):202-205. doi:10.1111/j.1398-9995.2006.00974.x.
Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol. 2007 Jul;120(1):164-170. doi:10.1016/j.jaci.2007.04.008.
Qin YE, Mao JR, Sang YC, Li WX. Clinical efficacy and compliance of sublingual immunotherapy with Dermatophagoides farinae drops in patients with atopic dermatitis. Int J Dermatol. 2014 May;53(5):650-655. doi:10.1111/ijd.12302.
Cadario G, Galluccio AG, Pezza M, et al. Sublingual immunotherapy efficacy in patients with atopic dermatitis and house dust mites sensitivity: a prospective pilot study. Curr Med Res Opin. 2007 Oct;23(10):2503-2506. doi:10.1185/030079907X226096.
Di Rienzo V, Cadario G, Grieco T, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, open, parallel-group study. Ann Allergy Asthma Immunol. 2014 Dec;113(6):671-673.e1. doi:10.1016/j.anai.2014.09.009.
Yu N, Luo H, Liang D, Lu N. Sublingual immunotherapy in mite-sensitized patients with atopic dermatitis: a randomized controlled study. Postepy Dermatol Alergol. 2021 Feb;38(2):69-74. doi:10.5114/ada.2021.104281.
Silny W, Czarnecka-Operacz M. Specific immunotherapy in the treatment of patients with atopic dermatitis--results of double blind placebo controlled study. Pol Merkur Lekarski. 2006 Dec;21(126):558-565. (in Polish).
Zhong H, Deng X, Song Z, et al. Immunological changes after ASIT in AD allergen-specific immunotherapy and their potential correlation with clinical response in patients with atopic dermatitis patients sensitized to house dust mite. J Eur Acad Dermatol Venereol. 2015 Jul;29(7):1318-1324. doi:10.1111/jdv.12813.
How to Cite
This work is licensed under a Creative Commons Attribution 4.0 International License.